Latest News
FDA Approves AstraZeneca's Imfinzi (durvalumab) as the First and Only Perioperative Immunotherapy for Patients With Muscle-Invasive Bladder Cancer
Details >FDA Approves Novartis' Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Details >FDA Approves Alnylam's Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Details >FDA Approves Exelixis' CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Details >Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
